Numan, a UK-based digital platform for men’s health, raised $40m in Series B funding.
The round was led by White Star Capital, with participation from existing investors Novator, Vostok New Global, Anthemis Exponential and Colle Capital, and new investor Hanwha Dream Fund.
Led by Sokratis Papafloratos, CEO & founder, Numan provides men with a digital service for the treatment for erectile dysfunction, premature ejaculation, hair loss, gut and lung health, and nutritional deficiencies. Numan works as a subscription service for healthcare treatments, allowing for medication and other products to be discreetly delivered to patients rather than requiring a pharmacy trip. All patients have ongoing access to a team of clinicians helping and informing them to make the best decisions for their health. Numan is also regulated by the Care Quality Commission as a registered healthcare provider.
The company intends to use the funds to continue to expand operations and its business reach, as well as the therapeutic areas it covers. Since its inception, the company has helped hundreds of thousands of men across the UK, with the business growing organically and via two strategic acquisitions in the UK and Sweden.
Numan is a UK-based digital health clinic for men that offers affordable direct-to-consumer health products and pharmaceuticals; personalised supplements; access to UK-based clinicians; a comprehensive suite of diagnostics, and empowering content that’s underpinned by science.
About White Star Capital
White Star Capital is an early-stage Venture Capital firm that invests in exceptional entrepreneurs building ambitious, data-driven businesses. Based out of London, New York, Montreal, Paris and Tokyo, our presence, perspective and people enable us to partner closely with our Founders to help them scale internationally from Series A onwards.